D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 81 Citations 22,239 275 World Ranking 11457 National Ranking 216

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Cancer

Tore Saxne mainly focuses on Rheumatoid arthritis, Internal medicine, Arthritis, Immunology and Infliximab. His work deals with themes such as Prednisolone, Prospective cohort study, Immunopathology, Pathology and Cartilage, which intersect with Rheumatoid arthritis. His study in Internal medicine is interdisciplinary in nature, drawing from both Cartilage oligomeric matrix protein and Surgery.

The various areas that he examines in his Arthritis study include Concomitant, Progressive disease, Adverse effect and Severity of illness. As part of one scientific family, Tore Saxne deals mainly with the area of Immunology, narrowing it down to issues related to the Oncology, and often Antirheumatic Agents, Breast cancer, Colorectal cancer, Skin cancer and Cancer. His Infliximab research is multidisciplinary, incorporating elements of Pharmacotherapy, Antibody and Etanercept.

His most cited work include:

  • Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. (528 citations)
  • Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis (470 citations)
  • IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. (463 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Rheumatoid arthritis, Internal medicine, Immunology, Arthritis and Pathology. His biological study spans a wide range of topics, including Reactive arthritis, Autoimmune disease, Connective tissue disease, Infliximab and Cohort. In his study, Observational study is inextricably linked to Physical therapy, which falls within the broad field of Internal medicine.

His Immunology research is multidisciplinary, incorporating perspectives in Prednisolone and Disease. His Arthritis research incorporates themes from Tumor necrosis factor alpha and Concomitant. Tore Saxne focuses mostly in the field of Pathology, narrowing it down to matters related to Cartilage and, in some cases, Cartilage oligomeric matrix protein, Osteoarthritis, Inflammation and Matrix.

He most often published in these fields:

  • Rheumatoid arthritis (53.76%)
  • Internal medicine (49.46%)
  • Immunology (30.47%)

What were the highlights of his more recent work (between 2010-2021)?

  • Rheumatoid arthritis (53.76%)
  • Internal medicine (49.46%)
  • Immunology (30.47%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Rheumatoid arthritis, Internal medicine, Immunology, Arthritis and Rheumatology. The concepts of his Rheumatoid arthritis study are interwoven with issues in Methotrexate, Cartilage oligomeric matrix protein, Antibody, Single-nucleotide polymorphism and Cohort. His Internal medicine study combines topics in areas such as Gastroenterology, Physical therapy and Surgery.

His Immunology study combines topics from a wide range of disciplines, such as Synovial fluid and Pneumococcal conjugate vaccine. The study incorporates disciplines such as Concomitant, Sustained remission, Tocilizumab and Abatacept in addition to Arthritis. His Rheumatology study also includes

  • Odds ratio together with Confidence interval,
  • Severity of illness and related Young adult.

Between 2010 and 2021, his most popular works were:

  • The role of the cartilage matrix in osteoarthritis (274 citations)
  • Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis (246 citations)
  • Delays in assessment of patients with rheumatoid arthritis: variations across Europe (90 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

Tore Saxne mostly deals with Rheumatoid arthritis, Internal medicine, Immunology, Rheumatology and Arthritis. His work in Rheumatoid arthritis tackles topics such as Cohort which are related to areas like Cause of death, Mortality rate, Confidence interval and Proportional hazards model. His Internal medicine study integrates concerns from other disciplines, such as Physical therapy and Weight-bearing, Surgery, Knee Joint.

His Immunology research is multidisciplinary, incorporating elements of Biomarker and Disease. His Rheumatology research integrates issues from Gastroenterology, Sports medicine, Cartilage oligomeric matrix protein, Pneumococcal conjugate vaccine and Conjugate vaccine. His work carried out in the field of Arthritis brings together such families of science as Young adult, Tocilizumab, Vaccination, Severity of illness and Abatacept.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.

Tore Saxne;Michael Palladino;Dick Heinegård;Norman Talal.
Arthritis & Rheumatism (1988)

831 Citations

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis

Lennart T H Jacobsson;Carl Turesson;Anders Gülfe;Meliha C Kapetanovic.
The Journal of Rheumatology (2005)

754 Citations

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

J Askling;C M Fored;Eva Baecklund;L Brandt.
Annals of the Rheumatic Diseases (2005)

577 Citations

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.

Klaus Bendtzen;Pierre Geborek;Morten Svenson;Lotta Larsson.
Arthritis & Rheumatism (2006)

562 Citations

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

Johan Askling;C. Michael Fored;Lena Brandt;Eva Baecklund.
Arthritis & Rheumatism (2005)

553 Citations

IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.

L.A.B. Joosten;M.M.A. Helsen;T. Saxne;F.A.J. van de Loo.
Journal of Immunology (1999)

522 Citations

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

J Askling;CM Fored;L Brandt;E Baecklund.
Annals of the Rheumatic Diseases (2005)

520 Citations

CARTILAGE OLIGOMERIC MATRIX PROTEIN: A NOVEL MARKER OF CARTILAGE TURNOVER DETECTABLE IN SYNOVIAL FLUID AND BLOOD

Tore Saxne;Dick Heinegård.
Rheumatology (1992)

503 Citations

Prognostic laboratory markers of joint damage in rheumatoid arthritis

Elisabet Lindqvist;Kerstin Eberhardt;Klaus Bendtzen;Dick Heinegard.
Annals of the Rheumatic Diseases (2005)

500 Citations

The role of the cartilage matrix in osteoarthritis

Dick Heinegård;Tore Saxne.
Nature Reviews Rheumatology (2011)

492 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Tore Saxne

Rikard Holmdahl

Rikard Holmdahl

Karolinska Institute

Publications: 130

Paul Emery

Paul Emery

University of Leeds

Publications: 91

Johan Askling

Johan Askling

Karolinska Institute

Publications: 80

Deborah P. M. Symmons

Deborah P. M. Symmons

University of Manchester

Publications: 69

Virginia B. Kraus

Virginia B. Kraus

Duke University

Publications: 69

Morten A. Karsdal

Morten A. Karsdal

University of Southern Denmark

Publications: 62

Xavier Mariette

Xavier Mariette

University of Paris-Sud

Publications: 62

Tore K. Kvien

Tore K. Kvien

University of Oslo

Publications: 56

Martin Englund

Martin Englund

Lund University

Publications: 48

Maxime Dougados

Maxime Dougados

Hôpital Cochin

Publications: 48

Josef S. Smolen

Josef S. Smolen

Medical University of Vienna

Publications: 43

Ronald F. van Vollenhoven

Ronald F. van Vollenhoven

University of Amsterdam

Publications: 43

Dick Heinegård

Dick Heinegård

Lund University

Publications: 43

Bernard Combe

Bernard Combe

University of Montpellier

Publications: 42

Tom W. J. Huizinga

Tom W. J. Huizinga

Leiden University Medical Center

Publications: 41

Désirée van der Heijde

Désirée van der Heijde

Leiden University Medical Center

Publications: 40

Trending Scientists

Craig Chambers

Craig Chambers

Google (United States)

Song Wang

Song Wang

University of South Carolina

Yu Sun

Yu Sun

University of Toronto

Dmitri I. Svergun

Dmitri I. Svergun

European Bioinformatics Institute

Guang S. He

Guang S. He

University at Buffalo, State University of New York

Susan Povey

Susan Povey

University College London

Momiao Xiong

Momiao Xiong

The University of Texas Health Science Center at Houston

Marie Stiborová

Marie Stiborová

Charles University

Michael D. West

Michael D. West

Advanced Cell Technology (United States)

Carlos D. Brody

Carlos D. Brody

Princeton University

Evert Van de Vliert

Evert Van de Vliert

University of Groningen

Donald Meichenbaum

Donald Meichenbaum

University of Waterloo

Janusz Jankowski

Janusz Jankowski

University College of Osteopathy

Nancy L. Bartlett

Nancy L. Bartlett

Washington University in St. Louis

Judith J. Prochaska

Judith J. Prochaska

Stanford University

Something went wrong. Please try again later.